Clinical Trials Directory

Trials / Completed

CompletedNCT02833675

Determination of Specific Biomarkers of Angioneurotic Crisis

Status
Completed
Phase
Study type
Observational
Enrollment
120 (actual)
Sponsor
University Hospital, Grenoble · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Diagnosis of angioedema (AE) is difficult especially in emergency room. Two forms should be evoked: histaminic AE (allergic or not, which represent 95% of cases) and bradykinic AE (hereditary or acquired deficiency, with or without C1 Inhibitor) rarer but with more severe prognosis. The distinction is based on clinical features (spontaneous crisis duration, presence of concomitant hives, atopic history...). Sometimes it could be difficult to make the difference. Nowadays, there is no biological marker of the crisis. The search for biomarkers could improve the diagnostic and therapeutic management of AE. Previous work has identified targets: D-dimer, C4, and VE-cadherin. We wanted to know the sensitivity and specificity of these markers. We conducted a prospective study evaluating the D-dimer assays, complement and VE-cadherin during an episode of AE. Three groups of patients were tested: bradykinic AE (peripheral or abdominal attacks), histaminic AE, and abdominal pain (non-bradykinic and non-histaminic etiology) at the time (day 0) and at distance from the crisis (D7).

Conditions

Timeline

Start date
2012-10-01
Primary completion
2017-08-01
Completion
2017-09-01
First posted
2016-07-14
Last updated
2017-09-29

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02833675. Inclusion in this directory is not an endorsement.

Determination of Specific Biomarkers of Angioneurotic Crisis (NCT02833675) · Clinical Trials Directory